Novo Nordisk Research Centre China (NNRCC)
Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company dedicated to combating serious chronic diseases such as diabetes, obesity, cardiovascular diseases, and rare blood disorders. The company has affiliates in 80 countries, serving over 45 million patients globally, with total net sales of 290.4 billion DKK (~305.6 billion CNY) in 2024.
With over 30 years in China, Novo Nordisk has expanded its investments across the full value chain, including R&D, production, and operations. Its “Dual Centres, Triple Engines” strategy in Beijing, Shanghai, and Tianjin strengthens local patient services and enhances its presence in the Chinese market.
Founded in 1997, NNRCC was the first research centre established by a multinational pharmaceutical company in China. Located in Zhongguancun Life Science Park, it covers 18,000 m² of state-of-the-art facilities. NNRCC focuses on early-stage novel drug research, from target identification and validation to drug candidate optimization and preclinical pharmacology, across areas such as diabetes, obesity, cardiovascular disease, MASH, and chronic kidney disease.
In March 2019, NNRCC launched INNOVO®, an open innovation platform aimed at fostering collaborations with universities, biotech companies, hospitals, and research institutes. INNOVO® contributes to local and global research pipelines, exploring fields including AI in drug discovery and other novel technologies.
NNRCC is committed to being a world-class research centre, driving innovation, facilitating translational research, and advancing pharmaceutical development in China and globally.